Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals declared a special dividend of $1.50 per share, totaling $22 million, following the close of its strategic transaction with Apotex Health. The company received $100 million in cash at closing, with an additional $11 million due for inventory and transition payments and a potential $10 million milestone payment, resulting in estimated net proceeds of $111 million. CFO John Hamm stated that remaining cash is projected to fund operations for over five years, with over $50 million in additional reserves for unexpected expenses or special opportunities. The company has reclassified revenue and expenses from its commercial brands as discontinued operations and will now focus on developing its ifetroban portfolio, with multiple clinical milestones expected in 2026 across DMD, systemic sclerosis, and IPF. Cumberland reported a net loss of $4.1 million for the second quarter and ended the period with total assets of $63 million, including approximately $4 million in cash and equivalents, after retiring its $5.2 million bank line of credit.

Universe Pharmaceuticals led Monday's biotech gainers with shares soaring nearly 100% after its SEC filing showed a narrowed net loss for the six months ended March 31, 2026. Revenue was $9.03 million and net loss was $1.55 million, or $2.76 per share, compared with a net loss of $3.28 million, or $9.44 per share, in the year-ago period. Cumberland Pharmaceuticals jumped over 38% ahead of its second-quarter 2026 results due Tuesday, following last month's sale of its branded portfolio to an Apotex Health unit for $100 million in cash. Autolus Therapeutics gained over 22% after reporting preliminary second-quarter AUCATZYL net product revenue of approximately $45 million, up 70% sequentially and more than 100% year over year. Other notable movers included Pulmonx, up over 30% after reaffirming full-year 2026 revenue guidance of $90 million to $92 million, and CAMP4 Therapeutics, which rose over 22% after receiving Australian clearance to begin a Phase 1/2 trial of CMP-002, satisfying a condition to raise up to $50 million in a private placement.